drugset

drugset / Trial / NCT07303803

A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

NCT07303803 ↗

Phase 2 Recruiting 300 enrolled Shanghai Jiao Tong University School of Medicine Chipscreen Biosciences, Ltd. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial aims to evaluate the efficacy and safety of chiglitazar as a combination therapy for patients with MASH and T2DM.

Timeline

Start: 2026-01-01
Primary completion: 2030-12-01
Completion: 2030-12-01

Publications

He K, Chen F, Shao R, Jiang W, Gu W, Huang Z, Gan Y, Wang Y, Wu H, Zhao Y, Zhang B, Gao L, Yan X, Yao C, Shen C, Ji P, Wei J, Bian Y, Lu Y, Abuduaini A, Liu L, Li H. Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol. BMJ Open. 2026 May 18;16(5):e116945. doi: 10.1136/bmjopen-2026-116945.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Chiglitazar	Unknown	48 mg	Oral
Background	Polyene Phosphatidylcholine	Small molecule	456 mg	—
Background	Vitamin E	Other / unclassified	100 mg	—

Indications